Science that you can verify.
Each PeptiNova compound is built on well-characterized metabolic pathways and published peptide research, and supported by a structured follow-up process that guides how our formulations evolve.
Figure 01 · [Molecular structure / mechanism diagram — caption and source]
MAGLUT
MAGLUT is a glucagon-like peptide-1 (GLP-1) analog that selectively activates its receptor. Its mechanism is related to glucose-dependent insulin secretion, reduced glucagon and a slight delay in gastric emptying in the early postprandial phase.
Figure 02 · [Molecular structure / mechanism diagram — caption and source]
TATRU
TATRU is a molecule designed to simultaneously activate the GIP, GLP-1 and glucagon receptors, reducing appetite, increasing satiety and regulating blood glucose. This three-pathway combination sets it apart from other peptides in its category.
Figure 03 · [Molecular structure / mechanism diagram — caption and source]
ZEPAT
ZEPAT is a dual GIP and GLP-1 receptor agonist. Its mechanism is related to the modulation of glucose-dependent insulin secretion, reduced glucagon and the regulation of caloric intake.
How we follow up and test
A structured process that accompanies every user and keeps our science team close to real-world use.
Structured intake
Each user starts with a structured intake that defines their protocol and goals.
Periodic follow-up
Regular check-ins to record tolerance and progress over time.
Internal review
Our science team reviews follow-up information in aggregate.
Continuous refinement
Insights feed back into how each formulation is developed and supported.
Ready to choose your formulation?
Compare the three compounds and their strengths, and select the formulation that fits your protocol.
[Regulatory notice — to be defined with legal/regulatory team.]